Co-Diagnostics’ (CODX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Co-Diagnostics (NASDAQ:CODX) in a report published on Tuesday,Benzinga reports. The brokerage currently has a $3.00 target price on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Co-Diagnostics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Co-Diagnostics has a consensus rating of “Moderate Buy” and a consensus price target of $2.00.

Co-Diagnostics Price Performance

NASDAQ CODX opened at $0.47 on Tuesday. The company has a market capitalization of $22.54 million, a price-to-earnings ratio of -0.41 and a beta of 0.93. Co-Diagnostics has a 12 month low of $0.23 and a 12 month high of $1.55. The company’s fifty day moving average price is $0.39 and its two-hundred day moving average price is $0.33.

Co-Diagnostics (NASDAQ:CODX) last released its earnings results on Thursday, August 14th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. Co-Diagnostics had a negative net margin of 3,588.33% and a negative return on equity of 69.49%. The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, analysts anticipate that Co-Diagnostics will post -1.22 EPS for the current year.

Hedge Funds Weigh In On Co-Diagnostics

A hedge fund recently raised its stake in Co-Diagnostics stock. Jane Street Group LLC raised its stake in Co-Diagnostics, Inc. (NASDAQ:CODX) by 314.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 166,254 shares of the company’s stock after acquiring an additional 126,105 shares during the period. Jane Street Group LLC owned 0.50% of Co-Diagnostics worth $47,000 as of its most recent SEC filing. 14.99% of the stock is owned by institutional investors and hedge funds.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.